Come on camry and stinkyfart, I'm waiting for you to post how you are shorting at 2.27
Since you are convinced it's going to zero, that should be a no-brainer for you
I win every time I get to buy this in higher quantity at a lower price. I'm buying every nickel down, in greater quantity than my last buy. I can keep this up no matter how low it goes, all the way to zero. When it ultimately rebounds, I may be kind and sell the shorts back some shares higher along the way, letting them cover for a loss, holding some for 4.25 which is where this stock at minimum belongs. ATRS is not going bankrupt.
The board has become so polluted with the likes of daviscupper, stinkyfart, and indabutt, that I will no longer waste time on it. These various aliases may very well all be one person. In any case, they will all disappear after ATRS bottoms and starts uptrending. Maybe then I'll start looking at the board again.
ATRS will have positive earnings within a few quarters. Good cash position and new products on the way. This is a bargain price. Buy when all bad news is out and only good news ahead.
I would have thought if they got approval that Medac would immediately be crowing about it on their website. Instead, I see no news about it on under their news tab.
Not sure how we'll find out today's outcome. Medac is privately owned and does not have to report anything. Will the FDA issue anything? Will Antares be notified and report it?
Antares has no motivation to hurry into a settlement unless Medac were to get full approval which is unlikely. Otrexup is already on the market.
Patent filing dates:
Medac Patent # 8664231
Antares Patent # 8480631
Medac is claiming they have patented drug concentrations greater than 25mg/ml, and self injector syringes since concentrations up to that have been listed as prior art. Both of these claims have copious prior art or pertain to obviousness.
However, if valid these claims pertain to all Antares injectors 15mg and greater as they are dispensed in a volume of 0.4ml.
Since this is a saline soluble formulation of methotrexate not a combination of drugs, and the disease to be treated has been identified, this is a very strong claim by Antares for obviousness. The obvious deduction being that if you want to increase the efficacy you increase the dosage dissolving more medication in formula. There are several similar recent cases having gone to trial but most pertain to a formulation of 2 drugs and decreasing the concentration of one to augment the interaction.
Medac did not notify Antares of their filing so they either disregarded the regulations or they actually filed prior to approval of Otrexup. Medac did not announce acceptance of the filing by the FDA until January 27, 2014. The FDA must accept or deny an application within 60 days of receipt, so this announcement implied a filing in late November. With a filing no more than a month prior to the Otrexup approval date, this puts this case into a gray area since clearly Medac knew that Antares would shortly have an approved product when they filed. Hopefully, the FDA will take this into account and give only a tentative approval to Medac, or find something missing and issue a CRL.
The patents have overlapping claims, that's the basis for a patent claim against Medac. Resolution via the courts could take years - which would be great for Antares. Antares has the stronger hand because they are first mover in the market.
Medac is trying to get their NDA using a 505(b)(2). The point of the litigation is that Antares claims they are a generic and improperly filed. So tentative approval is possible until litigation is settled. FDA will not rule on an issue to be settled by the courts. That is why full approval is very unlikely. There is a chance that the FDA will rule that something is incomplete and ask for re-submission. I see either tentative approval or CRL as positive for Antares.